The US Food and Drug Administration (FDA) has announced that it will be expanding its investigation into impurities in US generic drugs beyond angiotensin II receptor blockers (ARBs), medicines for high blood pressure.
Date:2019-09-03 Views:440
The US Food and Drug Administration (FDA) has announced that it will be expanding its investigation into impurities in US generic drugs beyond angiotensin II receptor blockers (ARBs), medicines for high blood pressure.
